Payment overview · 2025
General Payments
$2,502.17
123 reported records · 29 companies
Healthcare provider profile · identity verified
Rafael Miguel Rodriguez
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BRANDON, FL · NPI 1669449963
Verified facts
What the public records show
CMS Open Payments records show Rafael Miguel Rodriguez received $2,502.17 in general payments during 2025 across 123 reported records.
PFIZER INC. accounted for 6.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Briviact, Gamunex-C, Qulipta, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tecfidera by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gamunex-C by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AMPYRA as an associated drug or biological on 1518 records involving 947 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ampyra by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Austedo by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $171.89 | 6.9% | 10 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $167.96 | 6.7% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $164.95 | 6.6% | 12 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $164.33 | 6.6% | 9 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $162.36 | 6.5% | 5 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $147.04 | 5.9% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $135.71 | 5.4% | 10 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $126.23 | 5.0% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $125.93 | 5.0% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $112.53 | 4.5% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $97.58 | 3.9% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $86.58 | 3.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.29 | 3.4% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$76.46 | 3.1% | 3 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $75.07 | 3.0% | 3 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $68.45 | 2.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $67.78 | 2.7% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $65.67 | 2.6% | 4 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $58.10 | 2.3% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $57.98 | 2.3% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $53.67 | 2.1% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $45.80 | 1.8% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $43.62 | 1.7% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $33.48 | 1.3% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $31.41 | 1.3% | 1 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $23.90 | 1.0% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.12 | 0.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $17.36 | 0.7% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.92 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,502.17 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $199.05 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $171.89 | 10 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $167.96 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $148.25 | 9 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $147.04 | 9 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $135.71 | 10 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $126.23 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $112.53 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $94.81 | 7 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $86.58 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $85.29 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $84.41 | 5 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $76.46 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $75.07 | 3 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $65.67 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $58.10 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $57.98 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $53.67 | 3 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $43.62 | 2 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $36.58 | 3 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $36.17 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $33.48 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $33.06 | 1 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $31.85 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $31.41 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $28.19 | 1 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $26.41 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $25.25 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $23.74 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | MDD US Operations, LLC | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $16.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Briviact briviact |
2025 | Briviact | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | AMPYRA open payments reported associated product |
CMS Open Payments — General Payments 1518 supporting records · 947 recipient NPIs · example record 1232555387 |
Ampyra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 642 | 205 |
| Memantine Hcl | Memantine Hcl | 593 | 201 |
| Gabapentin | Gabapentin | 572 | 197 |
| Levetiracetam | Levetiracetam | 394 | 97 |
| Primidone | Primidone | 307 | 81 |
| Baclofen | Baclofen | 267 | 91 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 256 | 95 |
| Duloxetine Hcl | Duloxetine Hcl | 239 | 76 |
| Lamotrigine | Lamotrigine | 180 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 153 | 60 |
| Topiramate | Topiramate | 137 | 46 |
| Rasagiline Mesylate | Rasagiline Mesylate | 121 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 38 |
| Meloxicam | Meloxicam | 115 | 31 |
| Clonazepam | Clonazepam | 113 | 33 |
| Memantine Hcl Er | Memantine Hcl | 111 | 29 |
| Pregabalin | Pregabalin | 106 | 53 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 28 |
| Rivastigmine | Rivastigmine Tartrate | 63 | 24 |
| Sertraline Hcl | Sertraline Hcl | 61 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 59 | 11 |
| Lacosamide | Lacosamide | 56 | 11 |
| Divalproex Sodium Er | Divalproex Sodium | 55 | 11 |
| Aimovig Autoinjector | Erenumab-Aooe | 52 | suppressed |
| Prednisone | Prednisone | 51 | 27 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 50 | 19 |
| Oxcarbazepine | Oxcarbazepine | 50 | suppressed |
| Copaxone | Glatiramer Acetate | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 11 |
| Carbamazepine | Carbamazepine | 44 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 13 |
| Fingolimod | Fingolimod Hcl | 38 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 37 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 37 | suppressed |
| Rivastigmine | Rivastigmine | 37 | 14 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 36 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 17 |
| Emgality Pen | Galcanezumab-Gnlm | 34 | suppressed |
| Phenobarbital | Phenobarbital | 33 | suppressed |
| Zonisamide | Zonisamide | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Valproic Acid | Valproic Acid | 32 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | 13 |
| Soliris | Eculizumab | 27 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 23 | suppressed |
| Dalfampridine Er | Dalfampridine | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 20 | suppressed |
| Glatopa | Glatiramer Acetate | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Austedo | Deutetrabenazine | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | 13 |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 19 | suppressed |
| Teriflunomide | Teriflunomide | 19 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Keppra | Levetiracetam | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 15 | suppressed |
| Ampyra | Dalfampridine | 14 | suppressed |
| Tecfidera | Dimethyl Fumarate | 14 | suppressed |
| Briviact | Brivaracetam | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Lyrica | Pregabalin | 13 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,502.17 · 123 records | PFIZER INC. | AUSTEDO XR, BOTOX, BRIUMVI, Bafiertam, Briviact, CREXONT, Fintepla, Gamunex-C, Gocovri, HYQVIA, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, NURTEC ODT, Ocrevus Zunovo, PONVORY, QULIPTA, Qelbree, REXULTI, Radicava, Rystiggo, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, ZAVZPRET, Zilbrysq | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Briviact play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error